APA (7th ed.) Citation

Lavie, O., Edelman, D., Levy, T., Fishman, A., Hubert, A., Segev, Y., . . . Hochberg, A. (2017). A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. Archives of gynecology and obstetrics, 295(3), 751-761. https://doi.org/10.1007/s00404-017-4293-0

Chicago Style (17th ed.) Citation

Lavie, Ofer, David Edelman, Tally Levy, Ami Fishman, Ayala Hubert, Yakir Segev, Eli Raveh, Michal Gilon, and Avraham Hochberg. "A Phase 1/2a, Dose-escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of BC-819 (H19-DTA) in Subjects with Recurrent Ovarian/peritoneal Cancer." Archives of Gynecology and Obstetrics 295, no. 3 (2017): 751-761. https://doi.org/10.1007/s00404-017-4293-0.

MLA (9th ed.) Citation

Lavie, Ofer, et al. "A Phase 1/2a, Dose-escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of BC-819 (H19-DTA) in Subjects with Recurrent Ovarian/peritoneal Cancer." Archives of Gynecology and Obstetrics, vol. 295, no. 3, 2017, pp. 751-761, https://doi.org/10.1007/s00404-017-4293-0.